Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
245.62B
Market cap245.62B
Price-Earnings ratio
13.19
Price-Earnings ratio13.19
Dividend yield
3.25%
Dividend yield3.25%
Average volume
14.99M
Average volume14.99M
High today
$99.84
High today$99.84
Low today
$97.81
Low today$97.81
Open price
$99.51
Open price$99.51
Volume
12.90M
Volume12.90M
52 Week high
$105.84
52 Week high$105.84
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

The current Merck(MRK) stock price is $98.77, with a market capitalization of 245.62B. The stock trades at a price-to-earnings (P/E) ratio of 13.19 and offers a dividend yield of 3.2%.

During the trading session on 2025-12-09, Merck(MRK) shares reached a daily high of $99.84 and a low of $97.81. At a current price of $98.77, the stock is +1.0% higher than the low and still -1.1% under the high.

Trading volume for Merck(MRK) stock has reached 12.9M, versus its average volume of 14.99M.

Over the past 52 weeks, Merck(MRK) stock has traded between a high of $105.84 and a low of $73.31.

Over the past 52 weeks, Merck(MRK) stock has traded between a high of $105.84 and a low of $73.31.

MRK News

Barchart 9h
These 2 High-Yield Dividend Stocks Are Some of the Safest Buys Right Now

The Fed just reminded everyone that the path to lower rates won't be a straight line. In late October, policymakers delivered a second cut this year. The benchm...

Nasdaq 22h
Merck's CAPVAXIVE Added To Publicly Funded Adult Immunization Program In Saskatchewan

(RTTNews) - Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, announced Monday that the province of Saskatchewan has added CAPVAXIVE, a 21-vale...

Merck's CAPVAXIVE Added To Publicly Funded Adult Immunization Program In Saskatchewan
Simply Wall St 1d
Merck: Evaluating Valuation After Dividend Hike, New Drug Approvals and Upbeat Analyst Upgrades

Merck (MRK) has been in the spotlight after a cluster of investor friendly moves, from a higher dividend and fresh drug approvals to upbeat Wall Street commenta...

Merck: Evaluating Valuation After Dividend Hike, New Drug Approvals and Upbeat Analyst Upgrades

Analyst ratings

52%

of 27 ratings
Buy
51.9%
Hold
48.1%
Sell
0%

More MRK News

The Motley Fool 2d
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

With yields between 3.4% and 6.8%, you'll need to think carefully about the highest yields in the Dow before you buy them. Just because a stock offers a high y...

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Simply Wall St 3d
Is It Too Late To Consider Merck After Its Recent 20.3% Share Price Jump?

Wondering if Merck at around $100 a share still looks attractive or if the easy gains are behind it? This breakdown outlines key considerations to help you asse...

Is It Too Late To Consider Merck After Its Recent 20.3% Share Price Jump?
Nasdaq 3d
Do These 3 Healthcare Stocks Need a Checkup?

Key Points Pfizer has a sizable 6.8% yield and is down nearly 60% from its 2021 highs. Bristol Myers Squibb has a 5% yield and is off its 2023 highs by nearly...

Do These 3 Healthcare Stocks Need a Checkup?
Nasdaq 4d
Is This Pharmaceutical Giant a Buy After a Major Acquisition?

Key Points Merck's newest acquisition could help it launch a promising flu candidate. Several other ongoing developments are helping paint a bright post-Keytr...

Is This Pharmaceutical Giant a Buy After a Major Acquisition?
TipRanks 4d
Merck & Co. Closes $7 Billion Notes Offering

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...

The Wall Street Journal 5d
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

The ruling applies only to the subcutaneous formulation of the Rahway, N.J., company’s treatment, rather than the intravenous formulation, which Halozyme said i...

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
Benzinga 5d
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Pliant Therapeutics, Inc. (NASDAQ:PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline. PLRX stock i...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.